Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service trial of its Galleri test missed its primary endpoint.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service trial of its Galleri test missed its primary endpoint.